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Abstract 
The prevalence of COVID-19 in the world is rapidly increasing. Although some patients show mild symptoms of the 
virus, some others need special care due to the exacerbation of the disease. Therefore, invasive treatments are needed 
to treat these patients. Data were collected from PubMed and Google scholars at various time points up to the 2020 
academic year. The related keywords are listed as follows: "COVID-19", "Treatment", "Pathogenesis", and "Lung 
disorder". Studies have shown that although the use of ECMO and ventilation can provide oxygen to patients and 
improve their clinical status; these procedures can lead to the activation of inflammatory responses and the activation 
of the renin-angiotensin system. Inflammation and activation of the renin-angiotensin system are among the weak 
prognoses for COVID-19-infected patients. ECMO and ventilation treatment procedures are like double-edged 
swords, and monitoring patients during treatment is essential to prevent renin-angiotensin activation. 
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Introduction 
Coronavirus disease (COVID-19) is one of the 
pandemic infections affecting almost the whole 
world nowadays (1). The virus was first detected in 
Wuhan, China, in 2019. Although the disease is 
infecting many people around the world, there is no 
primary cure for it (2). On the other hand, some 
people with underlying diseases such as asthma, 
heart disease, and diabetes have been shown to have 
increased mortality rates (3, 4). Treatments 
commonly used to treat COVID-19-infected 
patients include antiviral drugs, corticosteroids, and 
supportive therapies (5). Extracorporeal membrane 
oxygenation (ECMO) and mechanical ventilation 
are also new therapies that are currently being used 
in many countries. These two methods increase the 
oxygen level of patients, as COVID-19 affects the 
lung and causes pulmonary dysfunction (6). 
Although these methods can improve the clinical 
status of patients to some extent, they are associated 
with some complications and abnormalities in lung 
function (7, 8). Here, we reviewed the impact of 
ECMO and mechanical ventilation on the clinical 
status of patients as well as the possible 
complications that these methods may have on the 
lungs of these patients. 
Extracorporeal membrane oxygenation 
ECMO is used to help patients with acute viral 
pneumonia associated with Covid-19 when blood 
oxygenation levels remain low even after 
ventilation. The WHO Temporary Guidelines for 
the Management of Covid-19 are general 
recommendations for the treatment of acute 
respiratory distress syndrome (ARDS) and in the 
form of venovenous (VV) ECMO for eligible 
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patients (9). However, its effectiveness is 
influenced by the experience and readiness of the 
intensive care unit. In some cases, patients with 
concomitant heart failure such as myocarditis, 
myocardial infarction, and cardiomyopathy may 
also need to use veno-arterial (VA) ECMO. 
Precautions on infection control are essential to 
prevent the further spread of the disease and to keep 
the medical team and other patients safe. Careful 
selection of the patient for ECMO is necessary 
because age and comorbidity change the outcome 
of the patient with Covid-19. However, several 
variables, including reversible lung disease, 
secondary lung infection, and antiviral drugs, and 
other disease-modifying factors, may affect ECMO 
results (10). ECMO is extracorporeal life support 
(ECLS) for people whose lives are at risk due to 
heart and lung failure (10). The mechanism of 
action of ECMO is to collect blood from the body, 
remove CO2, and supply oxygen to RBCs (11). 
Improvements have been reported in 57% of 
patients with respiratory failure and 41% of patients 
surviving with heart failure following ECMO use 
(12). Complications from ECMO are prevalent, the 
most common of which are bleeding due to 
systemic heparinization, platelet dysfunction, and 
hemodilution of blood clotting factors. Pulmonary 
hemorrhage is also common, and intracerebral 
hemorrhage is seen in 10-15% of patients. 
Hemolysis and systemic thromboembolism are 
among the rare complications of ECMO, and the 
rate of neurological complications is reported to 
vary between 3-47% (13). Also, septic 
complications are caused by repeated external 
manipulations of the ECMO circuit and may 
increase the risk of infection. ECMO may also alter 
serum concentrations of drugs due to increased 
distribution volume and decreased renal and hepatic 
function (14). There is also a possibility of 
secondary cardiac thrombosis following ECMO 
treatment (15). In general, although ECMO as a 
treatment option reduces mortality, almost all 
patients treated with it suffer from a systemic 
inflammatory response syndrome (SIRS) (16). 
When the patient's blood comes in contact with the 
surface of the circuit outside the body, a variety of 
coagulation and inflammatory cascades are 
activated. Platelets can mediate inflammation 
during ECMO use. The platelets adhere to the 
fibrinogen absorbed by the circuit, and platelet 
activation occurs mainly in response to thrombin 
production. Although the activation of the 
complement system, and the physical properties of 
the circuit also play a role. Platelets are also able to 
form leukocyte compounds, which cause platelet-
leukocyte interactions to secrete cytokines and anti-
inflammatory monocytes (17). Clinical and 
empirical evidence suggest that the SIRS 
mechanism of ECMO is an important event due to 
the activation of neutrophils and other leukocytes, 
caused by contact with the outer surface of the 
circuit, shear stress, the expression of inflammatory 
cytokines, coagulation, fibrinolytic pathways, and 
an increase in the concentration of bioactive lipids 
(18). This process is rapid, during which the 
activated neutrophils attach to the capillary/venular 
endothelium and are degranulated to produce 
cytokines and arachidonic acid metabolites (19). 
Endothelial dysfunction is associated with poor 
outcomes in patients, and even without direct 
contact with the circuit outside the body, it plays an 
essential role in the inflammatory response during 
ECMO (20). Changes in the expression of 
endothelial cell genes lead to the release of pro-
inflammatory factors, increased migration of 
leukocytes, and the penetration of neutrophils, 
which will lead to lung damage (17). For example, 
studies have shown that the use of ECMO leads to 
the expression of genes in endothelial cells that 
increase their expression can stimulate the immune 
system due to chemotaxis of immune cells. For this 
purpose, pdx1 is one of the genes whose expression 
is increased in endothelial cells during ECMO 
treatment. pdx1 increases the expression of 
receptors associated with innate immune 
stimulatory factors. On the other hand, in addition 
to pdx1, ICAM, VCAM and VEGF have been 
shown to increase their expression in endothelial 
cells (21, 22). Monocytes are also active in response 
to ECMO, but their activation appears to be slower 
than that of neutrophils. However, a number of 
inflammatory cytokines are secreted if monocytes 
are properly stimulated (23). The rapid increase in 
plasma concentrations of TNF-α and IL-8 almost 
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immediately after the onset of ECMO indicates that 
these cytokines are an essential mediator in the 
development of ECMO-related inflammation (16). 
According to the study by Ruan and colleagues, IL-
6 concentrations increased steadily during ECMO 
use and were inversely related to survival (24). This 
increased concentration in the lung was due to the 
onset of ECMO and was associated with 
parenchymal damage. However, those who 
survived ECMO were able to return the IL-6 
concentration to normal (25). In general, according 
to different studies, the leading cause of death in 
ARDS patients is organ failure, sepsis, 
inflammatory cytokines (IL-6, IL-8, IL-10), and 
immune cells. IL-10 is a significant immune 
regulator in SIRS or infection caused by pathogens, 
the level of which in ARDS patients has been 
linked to disease severity during ECMO. An 
increase in IL-10 predicts unsuccessful ECMO and 
death (26). During ECMO, the number and function 
of lymphocytes decrease significantly. Therefore, 
the number of lymphocytes should be closely 
monitored in patients with Covid-19 undergoing 
ECMO treatment. Finally, it is essential to consider 
the number of lymphocytes and IL-6 during ECMO 
to monitor and predict the patient's condition. 
Mechanical ventilation 
Ventilation is one of the treatment methods that 
improve the clinical condition of patients to a large 
extent by exchanging gas and providing sufficient 
oxygen to patients (27). Since Covid-19 is increased 
in the lungs of patients and leads to respiratory 
disorders, ventilation is used to treat them(28). In 
about 6% of patients, the use of ventilation leads to 
some side effects. One of these complications is the 
occurrence of nosocomial infections in patients. 
Other side effects of the hemodynamic change 
include loss of balance between intracellular and 
extracellular fluids and impaired blood pressure 
(29). However, the activation of the renin-
angiotensin system (RAS) and the onset of 
inflammation appear to be the most severe side 
effects that may occur in patients infected with 
Covid-19 after ventilation (30). RAS is one of the 
body's hormonal networks that play an essential 
role in regulating blood pressure, establishing 
homeostasis, and balancing fluid and electrolytes 
inside and outside the cell (31). This system 
consists of several components that act against each 
other. Angiotensin-converting enzyme-2 (ACE2) is 
one of these components. ACE2 is reported to be 
expressed on many cells, including the heart, lungs, 
and kidneys. ACE2 is also one of the main 
receptors of Covid-19  for entering the cell (32). 
Recent studies have shown that ACE2 expression 
increases during ventilation. It has also been shown 
that by activating the NF-kB pathway and the cells 
of the immune system, ACE2 produces 
inflammatory cytokines. It also causes endothelial 
(EC) dysfunction through the secretion of matrix 
metalloproteinase (MMPs) and produces reactive 
oxygen species (ROS) (33).Finally, it should be 
noted that the ACE2 expression in patients should 
be considered when using ventilators. This allows 
the use of the right strategies to reduce the 
expression of ACE2 and prevent inflammation 
Anesthesia agents 
The use of general anesthesia for patients admitted 
to the intensive care unit (ICU) who need 
ventilation devices is on the rise (34). Some patients 
infected with Covid-19 require invasive treatments 
such as intubation or ECMO due to their underlying 
disease as well as lung involvement (35). Currently, 
most studies have focused on how to sterilize 
anesthetics and prevent the transmission of 
infection. Also, there are some protocols designed 
to prevent anesthesiologists from getting infected 
with Covid-19 in the operating room (36). 
However, no study has been yet conducted on the 
side effects of the use of anesthetics, whether 
through inhalation or intravenously. Some 
anesthetics can cause bronchospasm while some 
lead to the activation of mast cells and their 
degranulation (37, 38). Degranulation of mast cells 
and basophils leads to an anaphylactic shock and 
shortness of breath. As shown in Table 1, the 
possible mechanisms of lung dysfunction caused by 
anesthetic agents are enumerated. 
Finally, although anesthetic agents are used for 
ventilation, some act like double-edged swords and 
can kill patients by stimulating basophils and mast 
cells and creating bronchospasm and anaphylactic 
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shocks. Therefore, assessing patients' sensitivity to 
anesthesia before surgery can lead to the design of 
appropriate strategies to prevent these unwanted 
complications. 
Table 1. Summary of potential anaphylactic reaction induction by anesthetic agents. 
Type of agents Human/Animal Clinical finding Ref. 
Combination sugammadex 
with desflurane 
Human Interaction sugammadex with circulating 
rocuronium molecules cause progression of 
bronchospasm 
(39) 
Inhalation agents Human Use of inhalation anesthesia agents cause 





Human use of a combination of dexmedetomidine 
and midazolam compare for 
dexmedetomidine alone cause reduce 
bronchospasm reaction 
(41) 
Ketamine Human Ketamine cause mast cell degranulation and 
anaphylactic reaction 
(42) 
Combination of sevoflurane 
and fentanyl 
Human cause increased histamine secretion by mast 
cell degranulation 
(43) 
Inhalational anesthesia with 
rocuronium-sugammadex 
Human Safe and reduce bronchospasm after surgery (44) 
 
 
Figure 1. Evaluation of ECMO and Ventilation Therapies for COVID-19 Infected Patients: ECMO and ventilation are 
used for patients in acute conditions. ECMO leads to many complications, including bleeding, thrombosis, and 
inflammation due to stimulation of TNF-α and IL-6 production. Ventilation also activates the renin-angiotensin 
system, which eventually leads to the expression of ACE2. ACE2 is one of the main receptors for COVID-19, which 
causes the virus to enter the cell. Abbreviation: ACE2: Angiotensin-converting enzyme 2 gene; ECMO: 
Extracorporeal membrane oxygenation; TNF-α: Tumor necrosis factor-alpha; IL-6: Interleukin 6.  
Conclusion 
Although the number of patients recovering from 
COVID-19 is increasing every day, no treatment 
has so far been found for this disease. Adjuvant 
therapy for these patients includes ECMO and 
ventilation. Although ventilation increases the 
supply of adequate oxygen to patients, it not only 
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increases the expression of ACE2 in patients' lung 
cells but also causes inflammatory responses. ACE2 
is one of the COVID-19 receptors for entering the 
cell. Therefore, when treating patients receiving 
ventilation, it is necessary to assess the level of 
ACE2 expression in patients' cells and increase 
their survival by preventing the progression of the 
disease.  
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